Does Retatrutide Cause Hair Loss?

Does retatrutide cause hair loss? Retatrutide is an investigational triple receptor agonist with no marketing authorisation in the UK or elsewhere, available only within authorised clinical trials. Published Phase 2 trial data did not identify hair loss as a prominent finding, though the full safety profile remains incomplete pending larger Phase 3 studies. Hair shedding associated with weight-loss programmes is most commonly attributed to telogen effluvium, a physiological response to rapid weight reduction, rather than a direct drug effect. This article outlines what is currently known from trial data and what to do if you notice hair shedding during a weight-loss programme.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and can only be accessed within an authorised clinical trial. It is an investigational triple receptor agonist studied for obesity and type 2 diabetes.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[4] It is an investigational medicine being studied for the management of obesity and type 2 diabetes. Unlike licensed treatments such as semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro), retatrutide has not been evaluated by the MHRA for routine clinical use, and no approval date can be given.

Retatrutide is a triple receptor agonist, acting on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors simultaneously. This triple mechanism distinguishes it pharmacologically from currently licensed dual or single agonists, though no authorised head-to-head comparisons with licensed medicines exist.

Because retatrutide is unlicensed, any product sold online and described as retatrutide is not a licensed medicine and may be falsified or unsafe. People interested in weight-management treatment should speak to their GP, who can discuss licensed options that are currently available on the NHS or privately.

Why do weight-loss treatments sometimes trigger hair shedding?

Hair shedding during weight loss is most commonly caused by telogen effluvium, a physiological response to rapid weight reduction or reduced caloric intake, rather than a direct toxic drug effect.

Hair shedding associated with weight-loss treatments is most commonly explained by a physiological process called telogen effluvium, rather than by a direct toxic effect of any specific medicine. Telogen effluvium occurs when a significant physical or metabolic stressor, such as rapid weight loss or a substantial reduction in caloric intake, causes a larger than usual proportion of hair follicles to enter the resting (telogen) phase simultaneously. The result is diffuse shedding, typically noticed two to four months after the triggering event.

This mechanism means that hair shedding during a weight-loss programme may reflect the degree and speed of weight reduction rather than a pharmacological property of the medicine itself. Nutritional factors, particularly inadequate protein intake, can compound the effect, as hair follicles require sufficient amino acids for normal cycling.

For licensed GLP-1 receptor agonist medicines, hair loss (alopecia) is listed as a known adverse effect in their UK Summary of Product Characteristics (SmPC). Whether this reflects telogen effluvium secondary to weight loss, a direct drug effect, or a combination of both has not been definitively established. The same uncertainty applies to investigational medicines studied in weight-loss trials, including retatrutide, where the contribution of rapid weight reduction to any observed hair shedding cannot easily be separated from a potential drug-specific effect.

What other side effects were reported in retatrutide clinical trials?

Phase 2 trial data most frequently reported gastrointestinal side effects including nausea, vomiting, diarrhoea and constipation. Hair loss was not identified as a prominent finding in published data.

Hair loss was not identified as a prominent finding in the published Phase 2 retatrutide trial data, though the trial programme is ongoing and the full safety picture will only emerge from the larger Phase 3 TRIUMPH and TRANSCEND studies.^[2] The most frequently reported adverse effects in Phase 2 data were gastrointestinal in nature, consistent with the class effects seen with other incretin-based medicines.

Commonly reported side effects in trial participants included:

• Nausea, particularly during dose escalation

• Vomiting and diarrhoea

• Constipation

• Decreased appetite

• Injection-site reactions

These effects were generally described as mild to moderate in severity and tended to diminish over time. As with licensed medicines in this class, the UK SmPC for authorised GLP-1 receptor agonists notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, though no risk magnitude is established.^[9] Whether a similar signal will emerge for retatrutide across the full trial programme remains to be determined.

Because retatrutide is investigational, its complete adverse effect profile is not yet established. Participants in authorised clinical trials are monitored closely, and any suspected adverse events should be reported to the trial team under the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Should I be worried about hair loss if I am on a weight-loss programme?

Diffuse hair shedding during a weight-loss programme is usually temporary and resolves once weight stabilises and nutrition is adequate. Speak to your GP before stopping any prescribed medicine.

Diffuse hair shedding during a weight-loss programme is relatively common and is usually temporary, resolving once body weight stabilises and nutritional intake is adequate. For most people, telogen effluvium does not lead to permanent hair loss, and regrowth typically occurs within several months of the shedding phase.

If you are currently taking a licensed weight-management medicine and notice increased hair shedding, the following steps are generally recommended:

• Do not stop your medicine without speaking to your GP or prescriber first, as abrupt discontinuation may not be necessary and could affect your treatment outcomes.

• Review your diet with a healthcare professional to ensure adequate protein and micronutrient intake, particularly iron, zinc and biotin, which support normal hair cycling.

• Contact your GP if shedding is severe, patchy rather than diffuse, associated with scalp changes, or if you have concerns about an underlying cause such as thyroid dysfunction or iron deficiency anaemia.

For people who are not currently on a weight-loss programme but are considering one, it is worth discussing the full benefit and risk profile of any licensed treatment with a GP or pharmacist before starting. There is no official link between retatrutide specifically and hair loss based on currently published trial data, and retatrutide itself is available only within an authorised clinical trial. Licensed weight-management treatments exist and can be discussed with a GP if you are looking for options that are currently available.

Frequently Asked Questions